PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
42.47
+0.36 (+0.85%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close42.11
Open41.95
Bid42.50 x 1000
Ask42.76 x 3000
Day's Range41.83 - 42.66
52 Week Range33.20 - 46.47
Volume22,938,626
Avg. Volume24,991,746
Market Cap245.497B
Beta (3Y Monthly)0.73
PE Ratio (TTM)10.73
EPS (TTM)3.96
Earnings DateJan 29, 2019
Forward Dividend & Yield1.44 (3.40%)
Ex-Dividend Date2019-01-31
1y Target Est45.35
Trade prices are not sourced from all markets
  • GuruFocus.com15 hours ago

    The Stable Value Stock Is Built to Weather Market Storms

    It is hard to say anything about McKesson (MCK) that we have not said before -- it is a high-quality business with extremely cheap shares. McKesson stock is not just cheap -- it's incredibly cheap. McKesson, for example, benefited tremendously when billions of dollars worth of branded drugs lost their patents and went generic between 2009 and 2015.

  • J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect
    Zacks22 hours ago

    J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect

    J&J's (JNJ) Pharmaceuticals segment is likely to face difficult comparisons in fourth quarter.

  • 3 Big Stock Charts for Thursday: Fiserv, Pfizer and PNC Financial Services Group
    InvestorPlace23 hours ago

    3 Big Stock Charts for Thursday: Fiserv, Pfizer and PNC Financial Services Group

    Wednesday was another winner for Wall Street, but just barely. The S&P 500 ended the day up 0.22%, having peeled back from a high of 2,625.786 to close at 2,616.10. The weight of the rally since late December is starting to weigh on investors. Financial stocks, led by bank stocks, carried most of the gain's weight. Bank of America (NYSE:BAC) was up 7.2% after swinging to a record-breaking fourth quarter profit. Yet, had it not been for sweeping bullishness from the financial sector, the overall market may not have ended the day with any gain at all. Ford Motor Company (NYSE:F) fell more than 6% on a disappointing fourth quarter. Snap (NYSE:SNAP) fared even worse, however, losing 13.7% after losing CFO Tim Stone … the second CFO resignation in less than a year. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Those disparate results are a microcosm of the environment right now, where the rising tide isn't lifting all boats equally. Going forward, traders will have to be more discriminate, and focus on stock charts like those of Fiserv (NASDAQ:FISV), Pfizer (NYSE:PFE) and PNC Financial Services Group (NYSE:PNC), which are better positioned to make trade-worthy moves. ### Fiserv (FISV) As odd as it may sound to cast a bullish light on Fiserv after it fell more than 4% at one point on Wednesday in response to news that it aims to acquire rival First Data (NYSE:FDC), in most regards the stumble was the capitulation the stock's needed for a while. * 10 Growth Stocks With the Future Written All Over Them Indeed, several clues already suggest that's exactly what happened yesterday. Click to Enlarge • The shape of yesterday's bar is telling in and of itself. After a poor open and then a sharp move to lower lows, the buyers came roaring back later in the day to force a close near the top of the range. The pivot has already been made. • Underscoring the potential capitulation is a huge volume surge. This indicates the last of the would-be sellers were finally flushed out. Now the buyers can start to trickle in without facing a headwind. • Curiously, yesterday's low around $68.50 was also last month's low, and last May's low. The bulls have drawn a line in the sand there. • Still, this is a scenario that requires a little follow-through to erase any lingering doubts that the reversal effort is for real. ### Pfizer (PFE) In yesterday's examination of the market's top three stock charts, the brewing bearishness of Merck (NYSE:MRK) was highlighted, but only because rivals like were also bumping into a headwind. When an entire group of stocks starts to struggle, it generally indicates a secular undertow that won't be easy to stop. In the meantime, Pfizer itself worked its way into a little more technical trouble, losing ground after being unable to press above its key moving averages too … moving averages that have formed bearish crosses while most other stocks are seeing bullish ones. Click to Enlarge • A couple of weeks ago the blue 20-day moving average line fell below the purple 50-day and gray 100-day moving average lines, and the 50-day line is close to breaking below the 100-day line. It all points to accelerating bearishness. • The selling volume has also been greater than the buying volume of late, even if both have been choppy. • The white 200-day moving average line at $40.27 has the potential to act as support should the potential selloff take shape, but there's an interim floor around $42.00 that would have to fail first before any of this weakness matters. ### PNC Financial Services Group (PNC) Finally, though almost all financial stocks were up on Wednesday, too many of them are now too overextended to bother stepping into now. Not PNC Financial Services Group, however. PNC is still closer to its recent low than not, with a whole lot of room to keep climbing. And, the recent chart action says this stock has built a near-perfect launch pad from which PNC will continue to rally. Click to Enlarge • Notice that PNC Financial Services shares have mostly stagnated since late last year, but within the past few days has started to log higher highs and higher closes. • Better yet, Wednesday's pullback to the blue 20-day moving average line was a perfect opportunity for the profit-takers to pile in. They didn't though, overwhelmed by the buyers waiting in the wings. Rising volume confirms more buyers are crawling out of the woodwork. • Zooming out to the weekly chart we can see the December pullback dragged PNC all the way to an established support line that extends back to March's lows. Each brush of that floor has resulted in a decent rebound. As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Top 10 Global Stock Ideas for 2019 From RBC Capital * 10 A-Rated Stocks the Smart Money Is Piling Into * 5 Best Bank ETFs for This Week's Earnings Avalanche Compare Brokers The post 3 Big Stock Charts for Thursday: Fiserv, Pfizer and PNC Financial Services Group appeared first on InvestorPlace.

  • Associated Press2 days ago

    Court rules against Pfizer in religious discrimination suit

    TRENTON, N.J. (AP) — A woman who said she was fired by a major pharmaceutical company because of her religious beliefs won a court victory Wednesday when a state appeals panel ruled that she didn't agree in an online form to waive her rights to sue.

  • Why Ligand Pharmaceuticals Tanked 25%
    Market Realist2 days ago

    Why Ligand Pharmaceuticals Tanked 25%

    Why Ligand Pharmaceuticals Tanked 25%Ligand PharmaceuticalsToday, US pharmaceutical firm Ligand Pharmaceuticals (LGND) fell 25% from yesterday’s closing price to a low of $98.86 for the day. At the same time, other pharmaceutical companies Amarin

  • Is Pfizer a Buy?
    Motley Fool2 days ago

    Is Pfizer a Buy?

    America's largest pharmaceutical company is about to show investors something they haven't seen in a while.

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Pfizer Inc.

    # Pfizer Inc ### NYSE:PFE View full report here! ## Summary * Perception of the company's creditworthiness is neutral * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for PFE with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $13.64 billion over the last one-month into ETFs that hold PFE are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Neutral The current level displays a neutral indicator. PFE credit default swap spreads are within the middle of their range for the last three years. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Pfizer (PFE) Gains But Lags Market: What You Should Know
    Zacks3 days ago

    Pfizer (PFE) Gains But Lags Market: What You Should Know

    Pfizer (PFE) closed at $42.73 in the latest trading session, marking a +0.85% move from the prior day.

  • Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer
    Zacks3 days ago

    Bristol-Myers' Drug Combination Gets EU Nod for Renal Cancer

    Bristol-Myers (BMY) gets EU approval for the immuno-oncology combination of Opdivo and low-dose Yervoy for the first-line treatment of patients with intermediate- and poor-risk advanced RCC.

  • Why Amarin Is Soaring in First Half of January
    Market Realist3 days ago

    Why Amarin Is Soaring in First Half of January

    Why Amarin Is Soaring in First Half of JanuaryStock price hikeOn January 11, Amarin (AMRN) closed at $18.00, which is 1.91% lower than its previous closing price. However, on January 10, 2019, the company closed at $18.35, almost 22% higher than its

  • Pfizer Gets FDA's Priority Review for Rare Disease Candidate
    Zacks3 days ago

    Pfizer Gets FDA's Priority Review for Rare Disease Candidate

    FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.

  • Here's How Pfizer Gained 20.5% in 2018
    Motley Fool3 days ago

    Here's How Pfizer Gained 20.5% in 2018

    While its industry was getting crushed, this big pharma surged forward.

  • Pharma Stocks Topple After House Dems Launch Drug-Pricing Probe
    Investor's Business Daily4 days ago

    Pharma Stocks Topple After House Dems Launch Drug-Pricing Probe

    House Democrats launched an investigation into a dozen pharmaceutical companies on Monday, focusing on drug prices and prompting shares to topple. AstraZeneca and Novo Nordisk fell hard.

  • This Biotech Stock Plunged On Its Looming Rivalry With Pfizer
    Investor's Business Daily4 days ago

    This Biotech Stock Plunged On Its Looming Rivalry With Pfizer

    Alnylam dipped Monday after the FDA agreed to review an amyloidosis treatment from Pfizer in just six months. Pfizer's drug would treat patients with abnormal protein building in the heart.

  • House Dems announce sweeping investigation of drug pricing
    Associated Press4 days ago

    House Dems announce sweeping investigation of drug pricing

    House Democrats announced a sweeping investigation Monday of the pharmaceutical industry's pricing practices, jockeying for the upper hand with the Trump administration on an issue that concerns Americans across the political spectrum. Oversight and Reform Committee Chairman Elijah Cummings said he's sent letters to 12 major drugmakers seeking detailed information and documents about pricing practices for brand-name drugs to treat diseases including cancer, diabetes, kidney failure and nerve pain. Cummings, a Maryland Democrat, said he wants to find out why prices have increased so dramatically for some existing medications, as well as how drug companies determine the prices of newly introduced medicines.

  • CNBC4 days ago

    House Democrats launch drug-pricing probe into a dozen major health-care companies

    AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.

  • InvestorPlace4 days ago

    Sell Amarin Stock on the Recent Takeover Rumors Rally

    Shares of cardiovascular health sciences company Amarin (NASDAQ:AMRN) surged 22% on Thursday. That continues an amazing ride for the maker of Vascepa, an Omega-3 fatty acids treatment to fight very high triglycerides. Amarin stock has soared from $3 in September to as high as $23 following its decisive REDUCE-IT study results. These results showed that Amarin's formulation of Omega-3 oils performs superiorly to other generic options. After years of criticism, Amarin demonstrated that it isn't "just another fish oil pill" as the bears had always retorted. Since the trial results, Amarin stock has remained highly volatile. Yes, it's clear Amarin has a viable commercial product on their hands now, but how many doctors will start prescribing it? InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 A-Rated Stocks the Smart Money Is Piling Into Can Amarin make it as a standalone operation or does it need a larger commercial backer? All these questions came to a head on Thursday when rumors broke that Pfizer (NYSE:PFE) or perhaps AstraZeneca (NYSE:AZN) was going to acquire Amarin outright. Amarin stock soared. ### Pfizer Buying Amarin? Probably Not Biotech journalist and Twitter heavyweight Adam Feuerstein weighed in on the Pfizer rumors, tweeting: "Help me with the logic here: $AMRN CEO John Thero just spent 4 days in [San Francisco] meeting face to face with investors while ALSO negotiating a $PFE takeout? People, please…" It's not uncommon for biotech management teams to pull out of conferences when they are about to be acquired. Particularly if Amarin already knew that Pfizer or someone else would bid for the company, why bother with in-person investor relations? There'd be more important business to attend to. Also, it's worth noting that Pfizer's comments at that same biotech conference didn't indicate that a deal is coming soon. Pfizer's CEO Albert Bourla noted that the company greatly stepped up its share buyback in 2018. It did so, Bourla said, in order to be able to boost R&D spending without hitting earnings. Adding to that Bourla commented rather directly that: "In the years before we had an issue with growth, so we were looking to buy revenues now or soon because this is what was lacking. Right now we are not in this situation. Right now we are in a situation that our R&D is very productive and I feel that mostly R&D type of deals is what we need to enhance even further our pipeline, given that we have higher confidence in our capabilities to do it, given that now we have very good focus on R&D." Pfizer's CEO stated it clearly: they don't need to acquire more drugs to obtain growth. The R&D pipeline is stuffed. Pfizer is unlikely to want to drop $8 billion or more to acquire Amarin at this time. ### Amarin: Short-Term Struggles A lot of Amarin stock bulls expected shares to fly up toward $30 in the immediate wake of the shockingly good REDUCE-IT trial data. Analysts have pegged future peak annual sales estimates for Vascepa at $2 billion to $4 billion sometime in the 2020s. Given Amarin's healthy patent position on the drug, this has the makings of being a blockbuster therapeutic. There's still the hitch that the company needs to convince the FDA to expand its marketing label for the drug later this year. However, given the strong data, this shouldn't be too much of an issue. For now, however, Amarin is still experiencing relatively soft sales. Amarin released guidance suggested that it will sell just $350 million of Vascepa in 2019. That was well short of the market's expectations. So far, since the REDUCE-IT data came out, Amarin has seen a decent bump in its weekly prescriptions. They're up from 11,000 pre-data release to 15,000 now. That's solid progress. Still, it's clear that without much more marketing and/or a wider label approval from the FDA, it will take awhile for Amarin to gain serious sales traction. ### Amarin Stock Takeaway That said, Amarin finds itself in a decent position nonetheless. It had $249 million in cash as of the latest report, suggesting that it has time to ramp up its sales operations as a separate company. Amarin lost $98 million on $205 million in revenues last year, suggesting it isn't especially close to profitability. Analysts forecast a much smaller, but still negative, net income figure for this year as well. Regardless, with that cash position, Amarin isn't desperate to find a suitor and can wait for an attractive offer. For now, I see AMRN as a solid trading stock. When there are short-term rips, such as the 22% pop on the Pfizer rumors, it is a good time to take profits. When the stock dips, say on weaker than expected earnings or prescription fills data, you can buy back in at a better price. In the short-term, I consider it highly unlikely that Pfizer or someone else like AztraZeneca is about to purchase Amarin. The actions from both companies' management teams suggest that a deal is not imminent. As such, it makes sense to ring the register on AMRN stock following the recent move from $13.50 at the start of the year to $18 now. If you like the Amarin story, you will get another chance to buy back in at a cheaper price as there are no immediate catalysts to drive Amarin stock higher. At the time of this writing, Ian Bezek held no positions in any of the aforementioned securities. You can reach him on Twitter at @irbezek. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Key Emerging-Market Stocks to Buy for Contrarian Investors * 7 Stocks at Risk of the Global Smartphone Slowdown * 7 Pharmaceutical Stocks That Just Raised Prices This Year Compare Brokers The post Sell Amarin Stock on the Recent Takeover Rumors Rally appeared first on InvestorPlace.

  • Benzinga4 days ago

    How To Approach Q4 Earnings: The Global Perspective

    Fears of a gradually slowing global economy started emerging mid-2018, alongside U.S. tariffs on goods from Canada, Mexico, the EU and, of course, China. More recent concerns about anemic oil and commodity prices and rapidly contracting productivity in China have only added to the uncertainty. One useful tool for getting an idea of a company's ability to weather the fallout of events like this is debt to capital ratios against its valuation and cash flow statistics.

  • Modern Value Investing: Adding to the Value Investing Toolbox
    GuruFocus.com4 days ago

    Modern Value Investing: Adding to the Value Investing Toolbox

    In chapter four of Sven Carlin's book, "Modern Value Investing: 25 Tools to Invest With a Margin of Safety in Today's Financial Environment," the author observed that almost a century had passed since Benjamin Graham laid out the foundational principles of value investing. Warning! GuruFocus has detected 7 Warning Signs with PFE. According to Carlin, investors should not be afraid to pay taxes.

  • MarketWatch4 days ago

    Pfizer's new drug applications for tafamidis accepted for filing by FDA

    Pfizer Inc's two new drug applications for tafamidis for the treatment of a fatal heart condition have been accepted for filing by the U.S. Food and Drug Administration, the company announced Monday. Pfizer submitted the NDAs based on two forms of the drug for treatment of transthyretin amyloid cardiomyopathy, a fatal condition where a transport protein in the blood misfolds and results in a build-up of amyloid fibrils in the heart, the company said. One of those forms, tafamidis meglumine, was granted priority review and has a July 2019 Prescription Drug User Fee Act target date for FDA review, the company said. A Phase 3 study of tafamidis meglumine met its primary endpoint, showing a significant reduction in mortality and frequency of cardiovascular-related hospitalizations over 30 months compared to placebo. Shares of Pfizer have fallen 1.8% in the year to date, while the S&P 500 has gained 3.5%.

  • Business Wire4 days ago

    US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy

    —FDA grants a Priority Review based on Phase 3 ATTR-ACT study findings in ATTR-CM—

  • Here Are the 2019 Dogs of the Dow
    Motley Fool4 days ago

    Here Are the 2019 Dogs of the Dow

    Dividend investors flock to this strategy to simplify their investing and earn solid returns. Here's how to join them this year.

  • Fiserv to buy First Data in $22B all-stock deal
    CNBC Videos2 days ago

    Fiserv to buy First Data in $22B all-stock deal

    Fiserv announced plans to buy First Data in an all-stock transaction the companies valued at $22 billion.

  • Democrats target drug prices
    CNBC Videos4 days ago

    Democrats target drug prices

    Democrats take on drug prices. Will a drug pricing battle hurt biotech? With CNBC's Melissa Lee and the Fast Money traders, Pete Najarian, Tim Seymour, Karen Finerman and Dan Nathan.

  • Stocks slip as corporate earnings season begins
    Yahoo Finance Video4 days ago

    Stocks slip as corporate earnings season begins

    U.S. stocks came under pressure amid signals of a widening trade deficit with China and trepidation over the start of corporate earnings season.